Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.01 +21.8%	$1.94	$1.33 ▼ $3.58	$94.69M	0.74	63,737 shs	45,078 shs
IVVD Invivyd	$0.80 +0.8%	$0.77	$0.35 ▼ $2.74	$95.89M	0.51	7.05 million shs	451,635 shs
PMN Promis Neurosciences	$0.63 -10.0%	$0.58	$0.38 ▼ $1.59	$20.60M	-0.04	2.88 million shs	563,032 shs
QNCX Quince Therapeutics	$1.68 -2.3%	$1.59	$0.51 ▼ $2.45	$90.24M	1.02	239,329 shs	126,612 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-13.61%	-30.38%	-10.81%	-6.78%	-32.65%
IVVD Invivyd	+1.63%	+10.60%	+8.63%	+12.64%	-25.19%
PMN Promis Neurosciences	0.00%	+18.64%	+34.62%	+32.08%	-41.67%
QNCX Quince Therapeutics	-6.01%	+3.61%	-3.37%	+105.01%	+201.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.8057 of 5 stars	3.5	5.0	2.0	1.7	0.0
IVVD Invivyd	3.6921 of 5 stars	3.6	4.0	3.1	3.3	0.6
PMN Promis Neurosciences	2.0541 of 5 stars	3.5	2.0	2.1	0.8	0.6
QNCX Quince Therapeutics	2.5681 of 5 stars	3.7	3.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.50	273.13% Upside
IVVD Invivyd	3.25	Buy	$5.85	631.89% Upside
PMN Promis Neurosciences	3.00	Buy	$4.33	587.83% Upside
QNCX Quince Therapeutics	3.30	Buy	$8.14	384.69% Upside

Current Analyst Ratings Breakdown

Latest PMN, ADAG, QNCX, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$9.00 ➝ $8.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
8/5/2025	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/5/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
8/5/2025	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$9.00
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/17/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$103.20K	917.51	N/A	N/A	$1.14 per share	1.76
IVVD Invivyd	$36.69M	2.61	N/A	N/A	$0.56 per share	1.43
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	-$169.93M	-$1.20	N/A	7.27	N/A	-389.01%	-165.24%	-99.71%	N/A
PMN Promis Neurosciences	$2.78M	-$0.05	N/A	N/A	N/A	N/A	-186.19%	-98.56%	N/A
QNCX Quince Therapeutics	-$56.83M	-$1.09	N/A	N/A	N/A	N/A	-187.49%	-42.47%	N/A

Latest PMN, ADAG, QNCX, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IVVD Invivyd	-$0.04	-$0.12	-$0.08	-$0.12	$23.16 million	N/A
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A
8/11/2025	Q2 2025	QNCX Quince Therapeutics	-$0.28	-$0.34	-$0.06	-$0.34	N/A	N/A
5/15/2025	Q1 2025	IVVD Invivyd	-$0.04	-$0.14	-$0.10	-$0.14	$34.45 million	$11.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.30	2.30
IVVD Invivyd	N/A	1.53	1.53
PMN Promis Neurosciences	N/A	3.36	3.36
QNCX Quince Therapeutics	1.45	5.00	4.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
IVVD Invivyd	70.36%
PMN Promis Neurosciences	50.13%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
IVVD Invivyd	25.40%
PMN Promis Neurosciences	6.11%
QNCX Quince Therapeutics	20.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
IVVD Invivyd	100	119.96 million	89.49 million	Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable
QNCX Quince Therapeutics	60	53.71 million	42.74 million	Optionable

PMN, ADAG, QNCX, and IVVD Headlines

Recent News About These Companies

JMP Securities Cuts Quince Therapeutics (NASDAQ:QNCX) Price Target to $8.00

August 14 at 2:53 AM | americanbankingnews.com

Quince Therapeutics (NASDAQ:QNCX) Price Target Cut to $8.00 by Analysts at JMP Securities

August 13 at 9:39 AM | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

August 12 at 9:25 PM | marketbeat.com

Quince Therapeutics price target lowered to $8 from $9 at Citizens JMP

August 12 at 4:47 PM | msn.com

Quince Therapeutics Reports Q2 2025 Financial Results

August 12 at 6:20 AM | msn.com

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 11 at 4:05 PM | businesswire.com

Quince Therapeutics (QNCX) Expected to Announce Quarterly Earnings on Tuesday

August 11 at 2:51 AM | americanbankingnews.com

Quince Therapeutics (QNCX) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

JMP Securities Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)

August 6, 2025 | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Citizens Jmp

August 6, 2025 | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Coverage Initiated at Citizens Jmp

August 6, 2025 | americanbankingnews.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Up 64.5% in July

August 6, 2025 | marketbeat.com

JMP Securities Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

August 6, 2025 | americanbankingnews.com

JMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform Recommendation

August 5, 2025 | msn.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by Analysts

July 21, 2025 | marketbeat.com

Brookline Capital Management Comments on QNCX Q3 Earnings

July 21, 2025 | marketbeat.com

Quince Therapeutics, Inc. (QNCX) - Yahoo Finance

July 17, 2025 | finance.yahoo.com

Quince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral Capital

July 17, 2025 | marketbeat.com

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

July 16, 2025 | businesswire.com

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan ...

July 12, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

July 10, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, ADAG, QNCX, and IVVD Company Descriptions

Adagene NASDAQ:ADAG

$2.01 +0.36 (+21.82%)

Closing price 03:57 PM Eastern

Extended Trading

$2.00 -0.01 (-0.55%)

As of 06:29 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Invivyd NASDAQ:IVVD

$0.80 +0.01 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 -0.02 (-3.04%)

As of 06:06 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Promis Neurosciences NASDAQ:PMN

$0.63 -0.07 (-10.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.63 0.00 (0.00%)

As of 06:22 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Quince Therapeutics NASDAQ:QNCX

$1.68 -0.04 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 +0.05 (+2.74%)

As of 04:57 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time